MC

520.2

+5.24%↑

SANES

8.168

+1.38%↑

SAF

284.7

-1.49%↓

BBVA

15.465

-0.55%↓

BNP

76.49

+0.18%↑

MC

520.2

+5.24%↑

SANES

8.168

+1.38%↑

SAF

284.7

-1.49%↓

BBVA

15.465

-0.55%↓

BNP

76.49

+0.18%↑

MC

520.2

+5.24%↑

SANES

8.168

+1.38%↑

SAF

284.7

-1.49%↓

BBVA

15.465

-0.55%↓

BNP

76.49

+0.18%↑

MC

520.2

+5.24%↑

SANES

8.168

+1.38%↑

SAF

284.7

-1.49%↓

BBVA

15.465

-0.55%↓

BNP

76.49

+0.18%↑

MC

520.2

+5.24%↑

SANES

8.168

+1.38%↑

SAF

284.7

-1.49%↓

BBVA

15.465

-0.55%↓

BNP

76.49

+0.18%↑

Search

Sartorius Stedim Biotech.

Open

BrancheFinanzen

174.8 -0.34

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

173.35

Max

176.45

Schlüsselkennzahlen

By Trading Economics

Einkommen

-23M

93M

Verkäufe

400K

745M

KGV

Branchendurchschnitt

75.693

27.333

EPS

1.18

Dividendenrendite

0.39

Gewinnspanne

12.43

Angestellte

10,030

EBITDA

-55M

201M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+26.36% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.39%

3.62%

Nächstes Ergebnis

16. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.8B

17B

Vorheriger Eröffnungskurs

175.14

Vorheriger Schlusskurs

174.8

Nachrichtenstimmung

By Acuity

31%

69%

143 / 534 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Sartorius Stedim Biotech. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Aug. 2025, 22:51 UTC

Ergebnisse

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H Rev $4.01B

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H Adj EPS $1.84

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H EPS $1.82

27. Aug. 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27. Aug. 2025, 23:39 UTC

Ergebnisse

Correction to Nvidia Earnings Article -- WSJ

27. Aug. 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Aug. 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27. Aug. 2025, 22:58 UTC

Ergebnisse

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27. Aug. 2025, 22:57 UTC

Ergebnisse

South32 FY Free Cash Flow $192 Million

27. Aug. 2025, 22:56 UTC

Ergebnisse

South32 FY Total Capital Expenditure $1.35 Billion

27. Aug. 2025, 22:56 UTC

Ergebnisse

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27. Aug. 2025, 22:55 UTC

Ergebnisse

South32 Net Cash $123 Million at June 30

27. Aug. 2025, 22:54 UTC

Ergebnisse

South32: Focused on Maintaining Strong Operating Momentum

27. Aug. 2025, 22:53 UTC

Ergebnisse

South32: $144 Million Remains to be Returned to Shareholders Under Program

27. Aug. 2025, 22:53 UTC

Ergebnisse

South32 Extends Capital Management Program for 12 Months

27. Aug. 2025, 22:52 UTC

Ergebnisse

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27. Aug. 2025, 22:51 UTC

Ergebnisse

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27. Aug. 2025, 22:51 UTC

Ergebnisse

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27. Aug. 2025, 22:50 UTC

Ergebnisse

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27. Aug. 2025, 22:50 UTC

Ergebnisse

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27. Aug. 2025, 22:45 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27. Aug. 2025, 22:44 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27. Aug. 2025, 22:44 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27. Aug. 2025, 22:43 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27. Aug. 2025, 22:43 UTC

Ergebnisse

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27. Aug. 2025, 22:42 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27. Aug. 2025, 22:42 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27. Aug. 2025, 22:40 UTC

Ergebnisse

Sandfire Resources Net Debt $123 Million at June 30

27. Aug. 2025, 22:40 UTC

Ergebnisse

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer-Vergleich

Kursveränderung

Sartorius Stedim Biotech. Prognose

Kursziel

By TipRanks

26.36% Vorteil

12-Monats-Prognose

Durchschnitt 221.44 EUR  26.36%

Hoch 240 EUR

Tief 174 EUR

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sartorius Stedim Biotech. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

6

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

202.7 / 211.7Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

143 / 534 Ranking in Finanzen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.